These results demonstrate that tirzepatide is associated with a higher percentage of patients achieving significant, clinically meaningful weight loss thresholds compared to semaglutide
55 Yubero-LahozS.PardoR.FarrM.O'MahonyB.TorrensM.MustataC.et al
Individual results may vary based on factors such as: Starting weight and BMI Dosage and treatment consistency Overall health, metabolism, and lifestyle habits Most patients begin to notice appetite control and steady weight changes within the first few weeks, with continued progress over several months of treatment
Safety Profile Comparison (2026 Data) Risk Factor Semaglutide (GLP-1) Bariatric Surgery Invasiveness Non-invasive (Injection) Invasive (Surgery) Common Risks Nausea, Vomiting, Constipation Infection, Bleeding, Blood Clots Serious Risks Pancreatitis, Gastroparesis Dumping Syndrome, Malnutrition Anesthesia Risk None Standard Surgical Risk Reversibility Fully Reversible Generally Permanent 2